Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and ...

NVO’s arch-rival, Lilly, markets tirzepatide, a dual GIP and GLP-1 receptor agonist, as Mounjaro for T2D and Zepbound for obesity. In the past three months, shares of Novo Nordisk and Lilly have ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Per the partial data released from that phase 3b clinical trial, over 72 weeks of once-weekly treatment with either Zepbound or Wegovy, patients taking Zepbound lost 20.2% of their weight on ...

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...

Walmart steel cage match (although we would totally watch). Instead, Walmart gave its logo a makeover fit for modern times—at least that was the idea. But people, well, they have feelings.

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

Walmart announced on Monday that it had unveiled a new logo, part of "a comprehensive brand refresh." The U.S.-based retailer boasted in a news release that the new look — its first change ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...